| Generate Bio Aims to Reveal Nature’s Protein Secrets, Create New Drugs | Frank Vinluan | 09/10/20 | Boston |
| Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally | Frank Vinluan | 09/03/20 | Boston |
| Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs | Frank Vinluan | 09/02/20 | Seattle |
| Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies | Sarah de Crescenzo | 08/26/20 | San Francisco |
| Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early | Sarah de Crescenzo | 08/26/20 | San Francisco |
| Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor | Sarah de Crescenzo | 08/17/20 | Boston |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| IgGenix Grabs $10M to Advance Antibody Treatments for Allergies | Sarah de Crescenzo | 08/05/20 | San Francisco |
| Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort | Sarah de Crescenzo | 07/29/20 | San Diego |
| Telehealth Firm AristaMD Adds $24M to Link Primary Docs With Specialists | Sarah de Crescenzo | 07/27/20 | San Diego |
| Olema Adds $54M to Start Human Tests of Breast Cancer Drug Candidate | Sarah de Crescenzo | 07/22/20 | San Francisco |
| Gilead Sciences Splashes Out $300M for Tizona Stake & Option to Acquire | Sarah de Crescenzo | 07/21/20 | San Francisco |
| Dewpoint, Merck Team Up to Tackle HIV Using Condensate Know-How | Sarah de Crescenzo | 07/15/20 | Boston |
| Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More | Sarah de Crescenzo | 07/10/20 | National |
| VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs | Sarah de Crescenzo | 07/09/20 | San Diego |
| Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs | Sarah de Crescenzo | 07/07/20 | Boston |
| On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO | Sarah de Crescenzo | 07/06/20 | San Francisco |
| Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs | Sarah de Crescenzo | 06/25/20 | Boston |
| In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo | Sarah de Crescenzo | 06/19/20 | Boston |
| Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs | Sarah de Crescenzo | 06/18/20 | San Diego |
| Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer | Sarah de Crescenzo | 06/17/20 | San Diego |
| Viela Bio Gets FDA Green Light for Rare Autoimmune Disease Treatment | Sarah de Crescenzo | 06/12/20 | National |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Atlas Venture Raises $400M Fund to Seed Another New Set of Biotechs | Sarah de Crescenzo | 06/05/20 | Boston |
| Accent, AstraZeneca Ink Cancer Drug Deal to Block RNA-Modifying Proteins | Sarah de Crescenzo | 06/04/20 | Boston |
| NodThera Adds $55M to Advance Drugs to Better Regulate Inflammation | Sarah de Crescenzo | 06/03/20 | Boston |
| After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Frank Vinluan | 05/29/20 | Boston |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| AbCellera Raises $105M to Advance Antibody Discovery Operations | Sarah de Crescenzo | 05/27/20 | Seattle |
| Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development | Sarah de Crescenzo | 05/26/20 | San Francisco |
